Literature DB >> 30532838

Torsades de pointes induced by garenoxacin in association with pacing failure in an elderly woman with VDD pacemaker.

Ryozo Yoshioka1, Masao Sakabe1, Hideshi Toyama1, Yusuke Muro1, Akira Fujiki1.   

Abstract

An 86-year-old woman was admitted to the hospital for syncope and convulsion 4 days after starting antibiotic therapy for pneumonia with oral garenoxacin 400 mg/day. She had a VDD pacemaker for complete atrioventricular (AV) block. Her electrocardiogram showed marked QT prolongation and during pacemaker interrogation pacing failure probably due to battery depletion induced torsades de pointes. After cessation of garenoxacin, QTc returned to normal range subsequently and a new pacemaker was implanted. In patients with risks of QT prolongation, garenoxacin should be used cautiously with QT interval monitoring.

Entities:  

Keywords:  Garenoxacin; Pacemaker; QT interval; Torsades de pointes

Year:  2011        PMID： 30532838      PMCID： PMC6265138          DOI： 10.1016/j.jccase.2011.01.006

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN： 1878-5409


  6 in total

1.  Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.

Authors:  M E Anderson; A Mazur; T Yang; D M Roden
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

2.  Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.

Authors:  Peter Milberg; Ekkehard Hilker; Shahram Ramtin; Yilmaz Cakir; Jörg Stypmann; Markus A Engelen; Gerold Mönnig; Nani Osada; Günter Breithardt; Wilhelm Haverkamp; Lars Eckardt
Journal:  J Cardiovasc Electrophysiol       Date:  2007-03-28

3.  Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome.

Authors:  Kotoe Takenaka; Tomohiko Ai; Wataru Shimizu; Atsushi Kobori; Tomonori Ninomiya; Hideo Otani; Tomoyuki Kubota; Hiroshi Takaki; Shiro Kamakura; Minoru Horie
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

Review 4.  Quinolones: cardioprotective or cardiotoxic.

Authors:  Demosthenes Katritsis; A John Camm
Journal:  Pacing Clin Electrophysiol       Date:  2003-12       Impact factor: 1.976

5.  Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.

Authors:  Zaiqi Wang; Dennis M Grasela; Gopal Krishna
Journal:  Clin Ther       Date:  2007-06       Impact factor: 3.393

6.  Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.

Authors:  Kanyu Miyamoto; Hirohisa Kawai; Ryuhei Aoyama; Hitoshi Watanabe; Keisuke Suzuki; Norihiro Suga; Wataru Kitagawa; Naoto Miura; Kazuhiro Nishikawa; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2009-11-14       Impact factor: 2.801
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.